Cargando…
Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
BACKGROUND: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian rea...
Autores principales: | Santini, Daniele, Cinieri, Saverio, Gasparro, Donatello, Bordonaro, Roberto, Guglielmini, Pamela Francesca, Chiuri, Vincenzo Emanuele, D'Angelillo, Rolando M, Ceresoli, Giovanni Luca, Fagnani, Daniele, Acquati, Mirko, Mencoboni, Manlio, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Panebianco, Fabiana, Beccaglia, Patrizia, Procopio, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779770/ https://www.ncbi.nlm.nih.gov/pubmed/33425672 http://dx.doi.org/10.1016/j.jbo.2020.100341 |
Ejemplares similares
-
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
por: Procopio, Giuseppe, et al.
Publicado: (2020) -
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
por: Procopio, G., et al.
Publicado: (2022) -
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022) -
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016) -
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)